Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors

Sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd
Study ID
NCT07769242
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-8203 Injection — DRUG
    SHR-8203 Injection Dose 1/ Dose 2/ Dose 3/ Dose 4

Study Details

This trial is a multicenter, open-label Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and efficacy of SHR-8203 injection in participants with advanced solid tumors.

Key Dates

First listed
Aug 17, 2026
Start date
Sep 1, 2026
Status verified
Aug 2026
Primary completion
Dec 30, 2029
Completion
Dec 30, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-8203 Injection

Primary Outcome Measure

The number of subjects with dose-limiting toxicity (DLT) [ Time Frame: From first dose of study treatment until the end of Cycle 1（up to 21 days） ]

Central Contacts

Related Studies